Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites.

IF 1.4 4区 医学 Q3 ALLERGY
Agnieszka Bogacz-Piaseczyńska, Andrzej Bożek, Maciej Pastuszczak, Jolanta Zalejska-Fiolka
{"title":"Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites.","authors":"Agnieszka Bogacz-Piaseczyńska,&nbsp;Andrzej Bożek,&nbsp;Maciej Pastuszczak,&nbsp;Jolanta Zalejska-Fiolka","doi":"10.5114/ada.2023.129456","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD).</p><p><strong>Aim: </strong>To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens.</p><p><strong>Material and methods: </strong>In this placebo-controlled study, 61 patients with moderate-to-severe AD allergy symptoms and HDM allergy were included. They received a 12 months' AIT with the use of HDM allergen extract or placebo. The authors adopted their AD improvement criterion after 1 year of AIT as a reduction of all examined indicators by at least 50% from the baseline for %BSA, TMS, and EASI scores. Additionally, the influence of individual HDM molecules on the final AIT effect was analysed.</p><p><strong>Results: </strong>Finally, from the 24 desensitised patients, 15 achieved a positive expected effect after 12 months of HDM AIT. None of the patients who received a placebo had an improvement in AD of at least 50% after 1 year of follow-up. Patients with polysensitisation less frequently achieved the expected HDM AIT effect than patients monosensitised to mites (<i>p</i> < 0.05). The presence of sensitisation to rDer p 1 (odds ratio = 4.35, 95% CI: 4.01-4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98-2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55-1.78) molecules significantly increased the efficacy of AIT. HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT effect. The presence of sensitisation to rDer p 1 (OR = 4.35, 95% CI: 4.01-4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98-2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55-1.78) molecules significantly increased the efficacy of AIT.</p><p><strong>Conclusions: </strong>HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b6/8d/PDIA-40-51077.PMC10485758.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2023.129456","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD).

Aim: To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens.

Material and methods: In this placebo-controlled study, 61 patients with moderate-to-severe AD allergy symptoms and HDM allergy were included. They received a 12 months' AIT with the use of HDM allergen extract or placebo. The authors adopted their AD improvement criterion after 1 year of AIT as a reduction of all examined indicators by at least 50% from the baseline for %BSA, TMS, and EASI scores. Additionally, the influence of individual HDM molecules on the final AIT effect was analysed.

Results: Finally, from the 24 desensitised patients, 15 achieved a positive expected effect after 12 months of HDM AIT. None of the patients who received a placebo had an improvement in AD of at least 50% after 1 year of follow-up. Patients with polysensitisation less frequently achieved the expected HDM AIT effect than patients monosensitised to mites (p < 0.05). The presence of sensitisation to rDer p 1 (odds ratio = 4.35, 95% CI: 4.01-4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98-2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55-1.78) molecules significantly increased the efficacy of AIT. HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT effect. The presence of sensitisation to rDer p 1 (OR = 4.35, 95% CI: 4.01-4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98-2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55-1.78) molecules significantly increased the efficacy of AIT.

Conclusions: HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT.

过敏原抗体IgE的分子谱分析可能决定过敏原免疫治疗对特应性皮炎和屋尘螨过敏患者的疗效。
过敏原免疫疗法(AIT)对特应性皮炎(AD)没有明确的推荐。目的:评价AIT对不同基线抗原分子谱的房尘螨敏感的AD患者房尘螨(HDM)的治疗效果。材料和方法:在这项安慰剂对照研究中,纳入了61例中度至重度AD过敏症状和HDM过敏患者。他们接受了为期12个月的AIT,使用HDM过敏原提取物或安慰剂。作者采用AIT治疗1年后AD改善标准,将所有检查指标的%BSA、TMS和EASI评分从基线降低至少50%。此外,还分析了单个HDM分子对最终AIT效果的影响。结果:最后,在24例脱敏患者中,15例在HDM AIT治疗12个月后达到预期阳性效果。在1年的随访后,接受安慰剂治疗的患者中没有一个在AD方面有至少50%的改善。与螨单致敏患者相比,多致敏患者达到预期HDM AIT效果的频率较低(p < 0.05)。对rDer p1(优势比= 4.35,95% CI: 4.01-4.56)和/或rDer p2 (or = 2.16, 95% CI: 1.98-2.33)和/或rDer f2 (or = 1.41, 95% CI: 1.55-1.78)分子致敏的存在显著提高了AIT的疗效。HDM AIT可能有助于中度至重度AD患者和对HDM敏感的附加治疗。不同的HDM分子可能会影响预期AIT效果的有效性。对rDer p1 (OR = 4.35, 95% CI: 4.01-4.56)和/或rDer p2 (OR = 2.16, 95% CI: 1.98-2.33)和/或rDer f2 (OR = 1.41, 95% CI: 1.55-1.78)分子致敏的存在显著提高了AIT的疗效。结论:HDM AIT可作为一种辅助治疗对HDM敏感的中重度AD患者有所帮助。各种HDM分子可能影响预期AIT的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
7.10%
发文量
107
审稿时长
6-12 weeks
期刊介绍: Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii is a bimonthly aimed at allergologists and dermatologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信